Trioar

Better Ideas. Better Technologies. Better Therapeutics.

Daejeon, South Korea · Founded 2021 · $27.2M raised

Headquarters
Daejeon
Employees
1–10
Founded
2021
Business Model
B2B
Total Funding
$27.2M
Last Round
$18.0M Series BJul 2025
Rounds
2

About

TriOar Inc. is a South Korean biotech company developing next-generation antibody-based therapeutics, focusing on antibody-drug conjugates (ADCs) and immuno-oncology (IO) platform technologies designed to improve the therapeutic index by simultaneously reducing toxicity and improving efficacy. The company's proprietary TROCAD platform features a dual-function targeting domain that enhances drug delivery while masking off-target effects, and its TROSIG linker-payload platform provides excellent stability, hydrophilicity, and payload compatibility. Founded in 2021 by seasoned scientists with years of experience in ADC and immunotherapy at Korean biotechs, TriOar is headquartered in Daejeon, South Korea.

Summary

Trioar is a Biotech company based in Daejeon, South Korea, founded in 2021. It has raised $27.2M in total across 2 rounds, most recently a $18.0M Series B round in Jul 2025. Investors include Woori Venture Partners, Shinhan Venture Investment and Hyundai Technology Investment.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJul 2025
$18.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Trioar on Indexed.vc
<a href="https://indexed.vc/companies/trioar"><img src="https://indexed.vc/api/badge/company/trioar" alt="Trioar on Indexed.vc" width="260" height="76" /></a>